Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: A phase I study

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 703-709

  Delva, R ^a   Pienkowski, T ^b   Tubiana, N ^c   Vanhoefer, U ^d   Longerey, B ^e   Douville, I ^e  

^a CENTRE PAUL PAPIN   (France)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Metastatic breast cancer; Oral vinorelbine; Paclitaxel; Phase I; Recommended dose

Indexed keywords

NAVELBINE; NVB; PACLITAXEL; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; NEUTROPENIA; PACLITAXEL; SALVAGE THERAPY; VINBLASTINE;

EID: 33947304617     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0324-4     Document Type: Article

References (15)

1. Marty M, Fumoleau P, Adenis A et al (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643-1649
2. Gridelli C, Manegold C, Mali P et al (2004) Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur J Cancer 40:2424-2431
3. 2 IV doses in cancer patients. J Clin Oncol abstract 2028
4. Martin M, Casado A, Segura PD et al (2000) Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11:85-89
5. Romero Acuna L, Langhi M, Perez J et al (1999) Vinorelbine and paclitaxel as first line chemotherapy in metastatic breast cancer. J Clin Oncol 17:74-81
6. Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. New Eng J Med 328:1323-1332
7. WHO handbook for reporting results of cancer treatment (1979) World Health Organisation, Geneva
8. EORTC manuel for clinical research in breast cancer (2004) EORTC Breast Cancer Cooperative Group, Hambourg
9. Culine S, Roch I, Pinguet F, Romieu G, Bressolle F (1999) Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patient previously exposed to anthracyclines. Int J Oncol 14:999-1006
10. Tortoriello A, Facchini G, Caponigro F et al (1998) Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47:91-97
11. Ibrahim NK, Buzdar AU, Valero V et al (2001) Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91:664-671
12. Vici P, Amodio A, Di Lauro L et al (2000) First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 58:3-7
13. Polyzos A, Tsavaris N, Kosmas C et al (2003) Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study. J Chemother 15:607-612
14. Cocconi G, Mambrini A, Quarta M et al (2000) Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 88:2731-2738
15. Spano JP, Bouillet T, Boaziz C et al (2004) Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer. Am J Clin Oncol 27:317-321